Option Care Health, Inc. (NASDAQ:OPCH) Insider Sells $1,030,926.96 in Stock

Option Care Health, Inc. (NASDAQ:OPCH) insider Michael Bavaro sold 30,996 shares of the company’s stock in a transaction dated Friday, February 28th. The shares were sold at an average price of $33.26, for a total transaction of $1,030,926.96. Following the completion of the sale, the insider now owns 44,974 shares in the company, valued at approximately $1,495,835.24. This trade represents a 40.80 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Option Care Health Price Performance

Shares of NASDAQ:OPCH opened at $34.60 on Thursday. The firm’s 50 day moving average is $29.38 and its two-hundred day moving average is $28.14. Option Care Health, Inc. has a 52 week low of $21.39 and a 52 week high of $34.85. The firm has a market capitalization of $5.72 billion, a P/E ratio of 29.08, a PEG ratio of 2.30 and a beta of 1.33. The company has a current ratio of 1.73, a quick ratio of 1.32 and a debt-to-equity ratio of 0.77.

Institutional Investors Weigh In On Option Care Health

Several large investors have recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in shares of Option Care Health by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 19,315,421 shares of the company’s stock valued at $448,118,000 after purchasing an additional 75,313 shares during the period. Wellington Management Group LLP increased its stake in shares of Option Care Health by 84.6% in the fourth quarter. Wellington Management Group LLP now owns 18,325,123 shares of the company’s stock valued at $425,143,000 after purchasing an additional 8,400,208 shares during the period. FMR LLC increased its stake in shares of Option Care Health by 134.0% in the third quarter. FMR LLC now owns 7,516,448 shares of the company’s stock valued at $235,265,000 after purchasing an additional 4,304,896 shares during the period. Westfield Capital Management Co. LP increased its stake in shares of Option Care Health by 10.2% in the third quarter. Westfield Capital Management Co. LP now owns 6,492,152 shares of the company’s stock valued at $203,204,000 after purchasing an additional 599,589 shares during the period. Finally, State Street Corp increased its stake in shares of Option Care Health by 1.4% in the third quarter. State Street Corp now owns 6,257,172 shares of the company’s stock valued at $195,849,000 after purchasing an additional 83,395 shares during the period. Institutional investors and hedge funds own 98.05% of the company’s stock.

Analysts Set New Price Targets

OPCH has been the topic of a number of recent analyst reports. UBS Group initiated coverage on shares of Option Care Health in a research note on Thursday, December 5th. They issued a “neutral” rating and a $26.00 target price on the stock. Bank of America raised shares of Option Care Health from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $26.00 to $33.00 in a research report on Monday, January 13th. JMP Securities reaffirmed a “market outperform” rating and set a $30.00 price objective (down previously from $31.00) on shares of Option Care Health in a research report on Friday, January 10th. Barrington Research boosted their price objective on shares of Option Care Health from $33.00 to $38.00 and gave the company an “outperform” rating in a research report on Thursday, February 27th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Option Care Health from $38.00 to $40.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $32.88.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.